Evaluations of technology assessments
Leveraging PHE’s expertise in quantifying value, modeling disease outcomes, and conducting cost-effectiveness analyses, PHE collaborates with clients to conduct strategic evaluations and responses to recent and forthcoming determinations of product value. Internationally, health technology assessments (HTAs) are commonly used to influence reimbursement decisions, but within the United States, their use is only starting to gain momentum through reviews by organizations such as the Institute for Clinical and Economic Review (ICER), which plans to expand its activities over the coming years. PHE collaborates with clients to ensure that these reviews account for a complete picture of the value innovations provide to patients and society and to assess their methodological soundness.
PHE not only has deep expertise in the theory, practice, and implications of value assessment, but also has collaborated with pharmaceutical clients on more than 20 unique ICER reviews, which have had meaningful impacts on ICER’s final recommendations, including several reversals.